AMNIMO
23.3.2020 07:02:05 CET | Business Wire | Press release
amnimo Inc. (Headquarters: Musashino City, Tokyo; President & CEO: Koichi [Casey] Taniguchi; hereafter, “amnimo”) starts developing an industrial-use LTE gateway, “Edge Gateway,” which is equipped with rich computing resources and a high level of robustness.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200322005056/en/
IoT is a mechanism by which a variety of devices are connected to each other via the network or the cloud service; these devices exchange information with each other. Recently, numerous approaches to the use of industrial-use IoT (IIoT) have been evolving in all types of industries. As IIoT continues to proliferate, examples of user work process improvements are increasing, but at the same time, we are witnessing operational issues such as suppressing failures in harsh external environments and being able to remotely deal with failures without going to the site. There have also been requests to process large volumes of data, such as video, using Edge in an advanced manner.
To resolve such issues, amnimo is developing the “Edge Gateway,” which is optimized for IIoT. The objective is to equip the Edge Gateway with LTE communication features that can be used in a wide variety of industries; in particular, to develop an optimal design for use in surveillance-camera systems.
[Characteristics of the Edge Gateway]
- Wide operating temperature range and power voltage range. Equipped with power circuits that are robust against noise and sudden outages, it has features for automatic recovery in case of a failure. This helps achieve stable operation even in harsh outdoor environments.
- Equipped with 2 GB of RAM and 32 GB eMMC for program storage space as the standard configuration, it can also be operated using a 2-TB SSD (Solid State Drive), enabling large-volume video data to be stored within the Edge Gateway.
- Equipped with a power-supply function for PoE(*1) compatible devices, it can be directly connected to a maximum of four IP cameras without using a PoE hub.
- The communication modules can accommodate two types of plastic SIM cards and eSIMs for a maximum of four different carrier SIMs, enabling the user to bypass communication failures by switching SIMs at high speeds in cases of emergency.
- Customer app development is possible on the Ubuntu OS; in addition, software development kits are provided for partners.
- Equipped with a VMS (Video Management System (*2)) as standard, simplifying the process of constructing small-, medium-, and large-scale surveillance systems.
- An extension port slot is internally provided in the Edge Gateway, enabling smooth addition of future functional extensions.
*1 Power over Ethernet: Specification wherein power is provided to the connected device(s) using Ethernet communication cables.
*2 System for saving and managing video captured using a surveillance camera.
In addition, we are developing a “device management system” to resolve issues related to operation on IIoT devices, such as the Edge Gateway. This device management system is a cloud service that enables initial configuration of IIoT devices, remote configuration and firmware updates, management of installation location, equipment life monitoring, log collection during operation, problem analysis and replacement, and transfer of configuration data for troubleshooting, thereby reducing the burden on the operator.
amnimo provides customer support for IIoT service and surveillance-camera systems, with the following objectives: “fast response and resolution for customer issues,” “value creation and innovation,” and “aim to grow with partners.”
About amnimo
amnimo was formed as a solely owned subsidiary of Yokogawa Electric Corporation as a new business to provide Industrial Internet of Things (IIoT) services in May 2018. With an excellent mobility, amnimo makes a swift decision and develops its business in a rapidly changing market. amnimo strengthens collaboration with customers and partner companies in various fields and countries to create new shared values by leveraging IIoT technologies.
To learn more, please visit https://amnimo.com/en/
The company names, organization names, and product names used in the document are registered trademarks or trademarks of the relevant organizations.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200322005056/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom